The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | The evolving role of datopotamab deruxtecan in lung cancer
Sewanti Limaye, MBBS, MD, MS, Sir H. N. Reliance Foundation Hospital & Research Centre, Mumbai, India, comments on the application of datopotamab deruxtecan (Dato-DXd) in non-small cell (NSCLC) and squamous lung cancer. While data from the TROPION-Lung01 (NCT04656652) and TROPION-Lung05 (NCT04484142) trials support its use in NSCLC, emerging evidence also suggests its efficacy in squamous lung cancer, albeit not as a first-line option. Currently, Dato-DXd is being administered to all comers in NSCLC, regardless of biomarker expression, due to its observed benefits in both high and low expressors. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
How does data apply for non-small cell and squamous? Now we have application of Datopotamab deruxtecan in both non-small cell and squamous. So non-small cell, adenocarcinoma and squamous. And we know largely the application and the benefit is better described in non-squamous, non-small cell. But emerging data also in squamous. Of course, not the first option, but really right now the application of Datopotamab deruxtecan in non-squamous, non-small cell lung cancer is without biomarker specific application because the benefit is being seen in all comers...
How does data apply for non-small cell and squamous? Now we have application of Datopotamab deruxtecan in both non-small cell and squamous. So non-small cell, adenocarcinoma and squamous. And we know largely the application and the benefit is better described in non-squamous, non-small cell. But emerging data also in squamous. Of course, not the first option, but really right now the application of Datopotamab deruxtecan in non-squamous, non-small cell lung cancer is without biomarker specific application because the benefit is being seen in all comers. It is a biomarker that’s seen expressed in most non-small cell lung cancers and in the TROPION-1 and TROPION-5 lung trials, the enhanced benefit was seen in people who were higher expressors, but the benefit was seen nevertheless. So right now for Datopotamab deruxtecan, we are applying in all comers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
